Market capitalization | $41.28b |
Enterprise Value | $49.05b |
P/E (TTM) P/E ratio | 38.85 |
EV/FCF (TTM) EV/FCF | 35.01 |
EV/Sales (TTM) EV/Sales | 3.17 |
P/S ratio (TTM) P/S ratio | 2.67 |
P/B ratio (TTM) P/B ratio | 3.88 |
Dividend yield | 3.76% |
Last dividend (FY24) | $0.81 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
19 Analysts have issued a Kenvue forecast:
19 Analysts have issued a Kenvue forecast:
Sep '24 |
+/-
%
|
||
Revenue | 15,459 15,459 |
1%
1%
|
|
Gross Profit | 8,935 8,935 |
3%
3%
|
|
EBITDA | 3,406 3,406 |
3%
3%
|
EBIT (Operating Income) EBIT | 2,760 2,760 |
5%
5%
|
Net Profit | 1,064 1,064 |
32%
32%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kenvue, Inc. engages in the provision of healthcare products services. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment includes oral care, baby care, women’s health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.
Head office | United States |
CEO | Thibaut Mongon |
Employees | 22,000 |
Website | www.kenvue.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.